Zusammenfassung
Immunglobulin E (IgE) besitzt eine Schlüsselrolle als Vermittler allergischer Reaktionen gegenüber Nahrungsmittel- oder Umweltallergenen, die bei der klinischen Ausprägung allergischer Symptome der Atemwege (allergische Rhinokonjunktivitis, Asthma bronchiale), der Haut (Urtikaria, atopische Dermatitis) und des Magen-Darm-Trakts (Nahrungsmittelallergien) von besonderer Bedeutung sind. Der rekombinante, humanisierte Antikörper Omalizumab, der seit 2005 in Deutschland für die Behandlung des schweren allergischen Asthma bronchiale für Kinder ab 12 Jahren zur Verfügung steht, hat für besondere Problemfälle seine therapeutische Wirksamkeit und – nach derzeitiger Datenlage – auch bei jüngeren Kindern seine gute Verträglichkeit belegt. Anti-IgE bietet über das Asthma bronchiale hinaus interessante Perspektiven für bisher schwer behandelbare, komplexe allergische Krankheitsbilder mit hohem Leidensdruck.
Abstract
Immunoglobulin E (IgE) plays a key role in mediating allergic reactions to food and environmental allergens, which are relevant for the expression of allergic symptoms of the airways (rhinoconjunctivitis, bronchial asthma), the skin (urticaria, atopic dermatitis), as well as the gastrointestinal tract (food allergens). The recombinant humanized antibody omalizumab, which became available in Germany in 2005 for the treatment of severe allergic asthma for children aged 12 years and above, has proved its therapeutic efficacy for special cases,as well as its safety in all age groups. In addition to bronchial asthma, anti-IgE offers interesting perspectives for the treatment of complex allergic diseases which have a strong impact on quality of life and have so far been difficult to control.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Beck LA, Marcotte GV, MacGlashan D et al. (2004) Omalizumab-induced reductions in mast cell Fcε expression and function. J Allergy Clin Immunol 114: 527–530
Bousquet J, Cauwenberge J, Cabrera P et al. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbation and emergency medical visits in patients with severe persistent asthma. Allergy 60: 302–308
Buhl R, Hanf G, Soler M et al. (2002) The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20: 1088–1094
Buhl R, Solèr M, Matz J et al. (2002) Omalizumab provides a long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 20: 73–78
Casale TB, Condemi J, LaForce C et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA 286: 2956–2967
Chang TW, Shiung YY (2006) Anti-IgE as a mast cell-stabilizing therapeutic agent. Rev J Allergy Clin Immunol 117: 1203–1212
Djukanovic R, Wilson SJ, Kraft M et al. (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170: 583–593
Fahy JV, Fleming HE, Wong HH et al. (1997) The effect on an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828–1834
Hamelmann E, Rolinck-Werninghaus C, Wahn U (2002) From IgE to anti-IgE: where do we stand? Allergy 57: 983–994
Hamelmann E, Rolinck-Werninghaus C, Wahn U (2003) Is there a role for anti-IgE in combination with specific allergen immunotherapy? Curr Opin Allergy Clin Immunol 3: 501–510
Humbert M, Beasley R, Ayres J et al. (2005) Benefits of Omalizumab as add-on-therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309–316
Kopp MV, Brauburger J, Riedinger F et al. (2002) The effect of anti-IgE-treatment on the in-vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 110: 728–735
Kuehr J, Brauburger J, Zielen S et al. (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescent with seasonal allergic rhinitis. J Allergy Clin Immunol 109: 274–280
Leung DYM, Sampson HA, Yunginger JW et al. (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348: 986–993
MacGlashan D Jr, McKenzie-White J, Chichester K et al. (1998) In vitro regulation of Fcε expression on human basophils by IgE antibody. Blood 91: 1633–1643
Milgrom H, Berger W, Nayak A et al. (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108: E36
Poole JA, Mantakasombut P, Rosenwasser LJ (2005) Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 114: 375–385
Rolinck-Werninghaus C, Hamelmann E, Keil T et al. (2004) The Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59: 973–979
Rolinck-Werninghaus E, Wahn U, Hamelmann E (2005) Anti-IgE therapy in allergic asthma. Curr Drug Targets Inflamm Allergy 4: 551–564
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wahn, U., Hamelmann, E. Anti-IgE-Therapie bei Kindern und Jugendlichen. Monatsschr Kinderheilkd 155, 134–137 (2007). https://doi.org/10.1007/s00112-006-1455-8
Issue Date:
DOI: https://doi.org/10.1007/s00112-006-1455-8